GeneDx Holdings (WGS) Non-Current Deffered Revenue (2020 - 2021)
GeneDx Holdings (WGS) posted quarterly Non-Current Deffered Revenue of $295.0 million for Q2 2021, down 0.64% sequentially from $297.0 million in Q1 2021.
GeneDx Holdings (WGS) Non-Current Deffered Revenue (2020 - 2021) Analysis & Trends
GeneDx Holdings has disclosed Non-Current Deffered Revenue across 2 years of filings, most recently posting $295.0 million for Q2 2021.
- In Q2 2021, Non-Current Deffered Revenue changed N/A year-over-year to $295.0 million; the TTM figure through Jun 2021 stood at $295.0 million (changed N/A YoY), while the FY2020 annual figure was $132.0 million, changed N/A from the prior year.
- Non-Current Deffered Revenue eased to $295.0 million in Q2 2021, from $297.0 million in the prior quarter.
- Over the last five years, Non-Current Deffered Revenue for WGS reached as high as $297.0 million in Q1 2021 and fell as low as $15.5 million in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Waters | 31,055.11 Bn | 31,054.65 Bn | 1.11 Bn | - |
| 2 | Thermo Fisher Scientific | 191.02 Bn | 187.77 Bn | 7.74 Bn | - |
| 3 | Danaher | 137.16 Bn | 131.47 Bn | 3.59 Bn | - |
| 4 | Idexx Laboratories | 42.82 Bn | 42.62 Bn | 722.74 Mn | 32.31 Mn |
| 5 | Natera | 39.09 Bn | 37.99 Bn | 696.04 Mn | 17.00 Mn |
| 6 | Agilent Technologies | 37.61 Bn | 35.81 Bn | 990.00 Mn | - |
| 7 | Iqvia Holdings | 34.23 Bn | 32.25 Bn | 1.36 Bn | - |
| 8 | Illumina | 28.14 Bn | 26.98 Bn | 721.00 Mn | - |
| 9 | Mettler Toledo International | 26.40 Bn | 26.33 Bn | 555.82 Mn | - |
| 10 | GeneDx Holdings | 2.10 Bn | 1.93 Bn | 68.21 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 295.05 Mn |
| Mar 31, 2021 | 296.95 Mn |
| Dec 31, 2020 | 131.99 Mn |
| Sep 30, 2020 | 15.50 Mn |